Des recommandations techniques et radiothérapie adjuvante des cancers du sein : pourquoi? Comment? Collaboration avec les sociétés savantes : SFRO/SNRO/SFPM, SFSPM, St Paul
Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. B LEYLAND-JONES et al.
Final analysis of NCIC CTG MA.27: A randomized phase III trial of Exemestane versus Anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. P GOSS et al.
